“The Global Pharmaceutical Contract Manufacturing market is estimated to grow at a CAGR of 6% in the first-half of the forecast period” says Visiongain report

01 October 2018
Pharma

Visiongain has launched a new pharma report: Pharma Leader Series: Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2018: Financial Performances, Services, Capacities, Mergers & Acquisitions, SWOT Analysis.

Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the benefits of contract manufacturing - lower costs, increased flexibility and external expertise - to focus resources on core competencies in drug development and marketing. CMOs are increasingly seen as a strategic partner for pharmaceutical companies, providing a one-stop-shop of services for formulation development and manufacturing throughout the lifecycle of a drug. The market-leading CMOs have grown through acquisitions and site expansions to offer almost all required services on a global scale. However, there is still a role to be played by specialist CMOs, particularly those that offer biological drug manufacturing services.

This updated study discusses market-leading companies worldwide, as well as the strategies they have employed to develop in recent years. Visiongain’s research and analysis explore opportunities and challenges for the top 50 pharma contract manufacturing organisations.

The lead analyst of the report commented "Visiongain has identified two major trends for leading API manufacturers in the coming 10 years: generics and HPAPIs. Demand for generic drugs is rising in developed markets - driven by the need to cut healthcare spending and patent expiries for major blockbusters - and in emerging markets - driven by rising disease prevalence and greater access to healthcare.

Demand will also rise for custom API manufacturing, particularly in the complex API and HPAPI market sectors. Visiongain believes that this market trend will be driven by increasing demands for targeted, small molecule therapies in chronic diseases, such as cancer."

Leading companies featured in the report include AbbVie Contract Manufacturing, Aenova Group, Aesica Pharmaceuticals, Ajinomoto Althea, Inc., Albany Molecular Research, Inc., Alcami Corporation, Alkermes plc, Almac Group, Amatsigroup, Aurobindo Pharma Ltd., Avid Bioservices Inc., Bayer AG, Baxter Biopharma Solutions, Biomay AG, Boehringer Ingelheim GmbH, Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Cardinal Health, Corden Pharmaceutical, Daito Pharmaceutical, Delpharm, Divis Laboratories Ltd., Dr. Reddy’s Laboratories Ltd., DPT Laboratories, Esteve Química, Evonik Degussa, Famar Health Care Services, Fareva, Fujifilm Diosynth Biotechnologies UK Ltd, GlaxoSmithKline plc, Huapont Medical, Lonza Group Ltd., Nipro Corporation, Paragon Bioservices Inc, Patheon Inc, Pfizer Inc./Pfizer CentreSource (PCS), Piramal Healthcare L, Recipharm A, Roche, Royal DSM NV, Shandong Xinhua Pharmaceutical, Siegfried, Teva API, Therapure Biopharma Inc., UPM Pharmaceuticals Inc., Vetter Pharmacuticals, Xcelience LLC, Xcellerex LLC, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceuticals

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1